Institution
Zhejiang Cancer Hospital
Also known as: 浙江省肿瘤医院
- 357running trials
- 109closed trials
- 12,764publications (OpenAlex)
Running trials
Not yet recruiting
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Not yet recruiting
PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer
Recruiting
Not yet recruiting
Not yet recruiting
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
Recruiting
Not yet recruiting
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
Recruiting
Recruiting
Not yet recruiting
Not yet recruiting
Not yet recruiting
Recruiting
Recruiting
Not yet recruiting
Not yet recruiting
Not yet recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Recruiting
Recruiting
Immunotherapy Combined With Carbon Ion Radiotherapy for Locally Advanced Cervical Cancer
Recruiting
Not yet recruiting
Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors
Recruiting
AMT-116 in Combination With AK112 in Patients With Lung Cancer
Recruiting
Recruiting
Recruiting
Recruiting
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
Not yet recruiting
A Prospective Observational Study of Senaparib in the Treatment of Epithelial Ovarian Cancer
Active, not recruiting
Not yet recruiting
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Recruiting
Recruiting
Not yet recruiting
JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer
Recruiting
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Recruiting
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Recruiting
Recruiting
Not yet recruiting
Recruiting
Not yet recruiting
Recruiting
Recruiting
Recruiting
Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Not yet recruiting
Not yet recruiting
Showing 50 of 357.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer64 recruiting
- Gastric and oesophageal cancer28 recruiting
- Metastatic breast cancer24 recruiting
- Ovarian cancer17 recruiting
- Colorectal cancer16 recruiting
- Cervical cancer15 recruiting
- Liver and biliary tract cancer15 recruiting
- Pancreatic cancer12 recruiting
- Childhood cancers11 recruiting
- Endometrial cancer10 recruiting
- Head and neck cancer9 recruiting
- Prostate cancer9 recruiting
- Brain metastases5 recruiting
- Diffuse large B-cell lymphoma5 recruiting
- Melanoma5 recruiting
- Triple-negative breast cancer5 recruiting
- Sarcoma4 recruiting
- Neuroendocrine tumours3 recruiting
- Thyroid cancer3 recruiting
- Bladder cancer2 recruiting
- Follicular lymphoma2 recruiting
- Kidney cancer2 recruiting
- Mantle cell lymphoma2 recruiting
- Obesity2 recruiting
- Acute myeloid leukaemia1 recruiting
- Chronic lymphocytic leukaemia1 recruiting
- Mesothelioma1 recruiting
- Stroke1 recruiting
Closed trials
Completed
ESCC Molecular Subtypes Based on Multidimensional Features of p53 and Their Clinical Significance
Completed
Completed
Completed
Completed
Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer
Completed
Completed
Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
Completed
Terminated
Completed
Study on the Mechanism of Ganoderma Lucidum Spore Powder in the Treatment of Depression
Completed
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Completed
Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Completed
Terminated
Completed
Completed
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Completed
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
Terminated
Terminated
AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer
Completed
Completed
Completed
Completed
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Completed
Completed
A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor
Completed
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Completed
Real World Study of Bone Metastases in Patients with Advanced Breast Cancer
Completed
Completed
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Completed
Completed
Completed
Completed
Showing 50 of 109.
Registry name variants (54)
Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.
Zhejiang Cancer Hospital
Hangzhou, Zhejiang 310000
380 trials
Zhejiang Cancer Hospital
Zhejiang, 310022
17 trials
Zhejiang Cancer Hospital
Hanzhou, Zhejiang 310022
7 trials
Zhejiang Medical University, Zhejiang Cancer Hospital
Hangzhou, 310022
3 trials
Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Hangzhou, Zhejiang 310022
2 trials
NCT06288360Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Contact: Yingli Zhang, PhD
NCT06288373Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
Contact: Yingli Zhang, PhD
Zhejiang Cancer Hospital (Site 0113)
Hangzhou, Zhejiang 310022
2 trials
Zhejiang Cancer Hospital (Site 0116)
Hangzhou, Zhejiang 310022
2 trials
Zhejiang Cancer Hospital (Site 0134)
Hangzhou, Zhejiang 310022
2 trials
Zhejiang Cancer Hospital (Site 0231)
Hangzhou, Zhejiang 310022
2 trials
Zhejiang Cancer Hospital (Site 0608)
Hangzhou, Zhejiang 310022
2 trials
Zhejiang Cancer Hospital (Site 1180)
Hangzhou, Zhejiang 310005
2 trials
Zhejiang Cancer Hospital (Site 2506)
Hangzhou, Zhejiang 310022
2 trials
Zhejiang Cancer Hospital (Site 3303)
Hangzhou, Zhejiang 310022
2 trials
Department of Hematology, Zhejiang Cancer Hospital
Hangzhou, Zhejiang 310000
1 trial
Contact: Xiaolin Yuan
Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Hangzhou, Zhejiang
1 trial
Contact: Jing Qin, MD, PhD
Zhejiang Cancer Hospital
Hanzhong, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital
Shanxi, 710061
1 trial
Zhejiang Cancer Hospital - 3204
Hangzhou, Zhejiang
1 trial
Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer hospital
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer hospital
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer hospital
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer hospital
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer hospital
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer hospital
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer hospital
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 0011)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 0101)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 0108)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 0171)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 0308)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 0435)
Hangzhou, Zhejiang 310022
1 trial
NCT06136624Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Contact: Study Coordinator
Zhejiang Cancer Hospital (Site 0510)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 0529)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital.... (Site 0814)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 0821)
Hangzhou, Zhejiang 310022
1 trial
Contact: Study Coordinator
Zhejiang Cancer Hospital (Site 1004)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 1214)
Hangzhou, Zhejiang 310005
1 trial
Zhejiang Cancer Hospital (Site 1309)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 1447)
Hangzhou, Zhejiang 310022
1 trial
Contact: Study Coordinator
Zhejiang Cancer Hospital (Site 2017)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 2117)
Hangzhou, Zhejiang 310022
1 trial
Contact: Study Coordinator
Zhejiang Cancer Hospital (Site 2205)
Hangzhou, Zhejiang 310022
1 trial
Contact: Study Coordinator
Zhejiang Cancer Hospital (Site 2211)
Hangzhou, Zhejiang 310022
1 trial
Contact: Toll Free Number
Zhejiang Cancer Hospital (Site 2409)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 2417)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 2511)
Hangzhou, Zhejiang 310022
1 trial
NCT07405151A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Contact: Study Coordinator
Zhejiang Cancer Hospital (Site 2727)
Hangzhou, Zhejiang 310022
1 trial
Contact: Study Coordinator
Zhejiang Cancer Hospital (Site 2829)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 3014)
Hangzhou, Zhejiang 310000
1 trial
Zhejiang Cancer Hospital (Site 3108)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 3109)
Hangzhou, Zhejiang 310022
1 trial
NCT07060807A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Contact: Study Coordinator
Zhejiang Cancer Hospital (Site 5008)
Hangzhou, Zhejiang 310022
1 trial
Zhejiang Cancer Hospital (Site 5012)
Hangzhou, Zhejiang 310022
1 trial
Conditions
Diseases this institution publishes on or runs trials for.
- Lung cancer238 works · 147 trials
- Gastric and oesophageal cancer101 works · 49 trials
- Colorectal cancer83 works · 25 trials
- Liver and biliary tract cancer75 works · 33 trials
- Ovarian cancer44 works · 32 trials
- Cervical cancer35 works · 25 trials
- Triple-negative breast cancer33 works · 14 trials
- Brain metastases32 works · 5 trials
- Metastatic breast cancer17 works · 49 trials
- Endometrial cancer14 works · 16 trials
- Thyroid cancer12 works · 10 trials
- Mesothelioma9 works · 2 trials
- Thymoma and thymic carcinoma4 works · 0 trials
Institution data: ROR 0144s0951 (CC0-1.0)Updated 15 Nov 2026